French biotech firm develops long-lasting flu vaccine
Register for free and continue reading
Join our growing army of changemakers and get unlimited access to our premium content
Osivax is seeking to prevent influenza outbreaks by targeting a specific part of the virus
Spotted: French-based Osivax is developing a universal flu vaccination designed to prevent various strains of the influenza virus for years. The vaccination will be more effective than current flu shots and will not need to be renewed annually.
“Currently available seasonal flu vaccines are limited in addressing all flu strains because they target highly variable regions of the virus,” said Alexandre Le Vert, CEO and co-founder of Osivax.
Osivax’s lead candidate version, OVX836, targets a particular part of the virus, the NucleoProtein. By targeting the NucleoProtein, it should stay effective even as the virus mutates. The formula has been successful in animal trials and is now being tested on humans.